*Nasdaq FSI: *Deficient and Delinquent: Issuer Failed to Meet NASDAQ Continued Listing Requirements, and Missed Regulatory Filing Deadline
Aclarion, Inc. is a healthcare technology company that employs magnetic resonance spectroscopy (MRS) and, and a biomarker to optimize clinical treatments. The Company’s signal processing software and expert system transform raw spectral MRS data into clear metabolic biomarkers to help physicians determine between painful and nonpainful discs of the lumbar spine. The Company is using augmented intelligence in a post-processing algorithm to analyze and quantifies the biomarker data, generating ratio metrics for each lumbar disc that are individualized to a normative data set. The Company’s technology is focused on the care of patients suffering from chronic low back pain.
|
|
|
|
| |
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
March 06, 2023 07:46 ET (12:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Copyright © 2023. All rights reserved.